Literature DB >> 8195616

False-positive rapid plasma reagin tests in human immunodeficiency virus infection and relationship to anti-cardiolipin antibody and serum immunoglobulin levels.

J M Rusnak1, C Butzin, D McGlasson, S P Blatt.   

Abstract

The incidence of biologic false-positive rapid plasma reagin (RPR) tests may be increased in human immunodeficiency virus (HIV) infection; however, injecting drug use has not been excluded as the cause. Review of 3371 periodic syphilis serology results from 1077 HIV-seropositive patients in the United States Air Force HIV Natural History Study between January 1986 and June 1992 revealed a cumulative biologic false-positive RPR rate of 1%. Most (6/9) were transient low-titer results associated with a recent acute infectious process. False-positive RPR tests did not appear to correlate with anticardiolipin antibody levels or serum IgG or IgA levels, which are increased in HIV infection. Although not statistically significant, there was a trend toward higher IgM levels in patients with biologic false-positive tests. Thus, the incidence of false-positive RPR in an HIV-infected population with a low risk of injecting drug use is similar to that in the general population, and the mechanism may correlate with elevated serum IgM levels.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8195616     DOI: 10.1093/infdis/169.6.1356

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  Validation of the INNO-LIA syphilis kit as a confirmatory assay for Treponema pallidum antibodies.

Authors:  A Ebel; L Vanneste; M Cardinaels; E Sablon; I Samson; K De Bosschere; F Hulstaert; M Zrein
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

Review 2.  Syphilis: review with emphasis on clinical, epidemiologic, and some biologic features.

Authors:  A E Singh; B Romanowski
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

Review 3.  Syphilis in adults.

Authors:  B T Goh
Journal:  Sex Transm Infect       Date:  2005-12       Impact factor: 3.519

4.  Nontreponemal tests in the diagnosis of neurosyphilis: an evaluation of the Venereal Disease Research Laboratory (VDRL) and the Rapid Plasma Reagin (RPR) tests.

Authors:  Rita Castro; Emília Simões Prieto; Filomena da Luz Martins Pereira
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

Review 5.  The endemic treponematoses.

Authors:  Lorenzo Giacani; Sheila A Lukehart
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

6.  Evaluation of a new competitive immunoassay (BioElisa Syphilis) for screening for Treponema pallidum antibodies at various stages of syphilis.

Authors:  A Ebel; L Bachelart; J M Alonso
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

7.  Anti-phospholipid antibodies and CD5+ B cells in HIV infection.

Authors:  T Grünewald; G R Burmester; W Schüler-Maué; F Hiepe; F Buttgereit
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

8.  Neurosyphilis in HIV-infected patients.

Authors:  J Bordón; C Martínez-Vázquez; M Alvarez; C Miralles; A Ocampo; J de la Fuente-Aguado; B Sopeña-Perez Arguelles
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-10       Impact factor: 3.267

9.  Frequency of Envoplakin and Type VII Collagen Autoantibodies and Co-occurrence with Other Skin-specific Autoantibodies in HIV-infected Patients and Uninfected Controls.

Authors:  René Reitermaier; Michael Skoll; Veronique Touzeau-Roemer; Maximilian C Aichelburg; Adelheid Elbe-Bürger; Wolfgang Bauer; Armin Rieger; Christopher Schuster
Journal:  Acta Derm Venereol       Date:  2021-11-24       Impact factor: 3.875

10.  Evaluation of SD BIOLINE Syphilis 3.0 for Rapid Diagnosis of Syphilis: Report from a Regional Sexually Transmitted Infection Reference Laboratory in North India.

Authors:  Bhanu Mehra; Sonali Bhattar; Shikhar Saxena; Deepti Rawat; Preena Bhalla
Journal:  J Lab Physicians       Date:  2016 Jan-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.